Aav capsid designs

Abstract

The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

1 . A recombinant expression vector comprising a nucleic acid encoding a polypeptide having a sequence selected from the group consisting of: SEQ ID NOs: 21-62, 67-799, 802-1725, and 1729-1986. 
     
     
         2 . An isolated AAV capsid protein comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs: 21-62, 67-799, 802-1725, and 1729-1986. 
     
     
         3 .- 7 . (canceled) 
     
     
         8 . An recombinant expression vector comprising a nucleic acid sequence encoding the isolated AAV capsid protein of  claim 2 . 
     
     
         9 .- 10 . (canceled) 
     
     
         11 . A recombinant AAV (rAAV) comprising the isolated AAV capsid protein of  claim 2 . 
     
     
         12 .- 13 . (canceled) 
     
     
         14 . A host cell containing a recombinant expression vector of  claim 8 . 
     
     
         15 .- 17 . (canceled) 
     
     
         17 . A method for delivering at least one transgene to a subject comprising administering a rAAV of  claim 11  to a subject, wherein the rAAV comprises the at least one transgene, and wherein the rAAV infects cells of a target tissue of the subject. 
     
     
         18 . A method for generating a somatic transgenic animal model comprising administering a recombinant rAAV of  claim 11  to a non-human animal, wherein the rAAV comprises at least one transgene, and wherein the rAAV infects cells of a target tissue of the non-human animal. 
     
     
         19 . The method of  claim 17 , wherein the at least one transgene is a protein coding gene or encodes a small interfering nucleic acid. 
     
     
         20 .- 23 . (canceled) 
     
     
         24 . The method of  claim 17 , wherein the target tissue is liver, central nervous system (CNS), bone, cartilage, ocular, gastrointestinal, respiratory, breast, pancreas, urinary tract, or uterine tissue. 
     
     
         25 .- 28 . (canceled) 
     
     
         29 . The method of  claim 17 , wherein the rAAV is administered intravenously, transdermally, intraocularly, intrathecally, orally, intramuscularly, subcutaneously, intranasally, or by inhalation. 
     
     
         30 . The method of  claim 17 , wherein the subject is selected from a human, a mouse, a rat, a rabbit, a dog, a cat, a sheep, a pig, and a non-human primate. 
     
     
         31 .- 35 . (canceled) 
     
     
         36 . A kit comprising:
 a container housing a recombinant AAV having an isolated AAV capsid protein of  claim 2 .   
     
     
         37 . (canceled) 
     
     
         38 . The isolated AAV capsid protein of  claim 2 , wherein the capsid protein is a VP1 capsid protein, a VP2 capsid protein, or a VP3 capsid protein. 
     
     
         39 .- 41 . (canceled) 
     
     
         42 . The recombinant expression vector of  claim 1 , wherein the nucleic acid encodes a V1 capsid protein, a VP2 capsid protein, or a VP3 capsid protein. 
     
     
         43 .- 50 . (canceled) 
     
     
         51 . The recombinant expression vector of  claim 1  comprising a nucleic acid encoding a polypeptide having a sequence selected from the group consisting of: SEQ ID NOs: 124, 149, 161, 175, and 358. 
     
     
         52 . The recombinant expression vector of  claim 1  comprising a nucleic acid encoding a polypeptide having a sequence selected from the group consisting of: SEQ ID NOs: 149, 152, 157, and 182. 
     
     
         53 . The recombinant expression vector of  claim 1  comprising a nucleic acid encoding a polypeptide having a sequence selected from the group consisting of: SEQ ID NOs: 46, 56, 67, 81, 224, 326, and 358. 
     
     
         54 . The isolated AAV capsid protein of  claim 2  comprising a nucleic acid encoding a polypeptide having a sequence selected from the group consisting of: SEQ ID NOs: 124, 149, 161, 175, and 358. 
     
     
         55 . The isolated AAV capsid protein of  claim 2  comprising a nucleic acid encoding a polypeptide having a sequence selected from the group consisting of: SEQ ID NOs: 149, 152, 157, and 182. 
     
     
         56 . The isolated AAV capsid protein of  claim 2  comprising a nucleic acid encoding a polypeptide having a sequence selected from the group consisting of: SEQ ID NOs: 46, 56, 67, 81, 224, 326, and 358.